Barclays PLC Argenx Se Call Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$434.22 - $551.9 $4.82 Million - $6.13 Million	-11,100 Reduced 41.11%	15,900 $8.62 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $9.61 Million - $12.2 Million	27,000 New	27,000 $11.6 Million
Q4 2023 Feb 15, 2024	BUY	$338.91 - $506.01 $1.76 Million - $2.63 Million	5,200 New	5,200 $1.98 Million
Q4 2020 Feb 11, 2021	SELL	$248.13 - $308.36 $2.93 Million - $3.64 Million	-11,800 Reduced 51.08%	11,300 $3.32 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $1.74 Million - $2.23 Million	23,100 New	23,100 $1.75 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.